ECSP23057264A - Inhibidores de cdk2 y métodos de uso de los mismos - Google Patents

Inhibidores de cdk2 y métodos de uso de los mismos

Info

Publication number
ECSP23057264A
ECSP23057264A ECSENADI202357264A ECDI202357264A ECSP23057264A EC SP23057264 A ECSP23057264 A EC SP23057264A EC SENADI202357264 A ECSENADI202357264 A EC SENADI202357264A EC DI202357264 A ECDI202357264 A EC DI202357264A EC SP23057264 A ECSP23057264 A EC SP23057264A
Authority
EC
Ecuador
Prior art keywords
methods
cdk2
cdk2 inhibitors
inhibitors
disorders
Prior art date
Application number
ECSENADI202357264A
Other languages
English (en)
Inventor
Louise Clare Kirman
Carl Eric Schwartz
Thomas P Blaisdell
Dale A Porter
Wojtek Michowski
John Feutrill
John Paul Sherrill
Original Assignee
Cedilla Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedilla Therapeutics Inc filed Critical Cedilla Therapeutics Inc
Publication of ECSP23057264A publication Critical patent/ECSP23057264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos, composiciones de los mismos y métodos de uso de los mismos para la inhibición de CDK2, y el tratamiento de enfermedades y trastornos relacionados con CDK2.
ECSENADI202357264A 2021-01-29 2023-07-27 Inhibidores de cdk2 y métodos de uso de los mismos ECSP23057264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163143360P 2021-01-29 2021-01-29

Publications (1)

Publication Number Publication Date
ECSP23057264A true ECSP23057264A (es) 2023-09-29

Family

ID=82654899

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202357264A ECSP23057264A (es) 2021-01-29 2023-07-27 Inhibidores de cdk2 y métodos de uso de los mismos

Country Status (21)

Country Link
US (2) US20240174680A1 (es)
EP (1) EP4284365A4 (es)
JP (1) JP2024505261A (es)
KR (1) KR20230142745A (es)
CN (1) CN117177744A (es)
AU (1) AU2022214618A1 (es)
BR (1) BR112023015210A2 (es)
CA (1) CA3208618A1 (es)
CL (1) CL2023002223A1 (es)
CO (1) CO2023010023A2 (es)
CR (1) CR20230362A (es)
DO (1) DOP2023000145A (es)
EC (1) ECSP23057264A (es)
GE (1) GEAP202316332A (es)
IL (1) IL304728A (es)
JO (1) JOP20230170A1 (es)
MX (1) MX2023008968A (es)
PE (1) PE20240050A1 (es)
PH (1) PH12023552079A1 (es)
TW (1) TW202239402A (es)
WO (1) WO2022165513A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202316332A (en) 2021-01-29 2023-12-11 Cedilla Therapeutics Inc Cdk2 inhibitors and methods of using the same
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
EP4358954A4 (en) 2021-06-26 2025-09-03 Cedilla Therapeutics Inc CDK2 INHIBITORS AND METHODS OF USE THEREOF
WO2024026486A2 (en) * 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3262943A1 (en) * 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
CA3263133A1 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
US20260014146A1 (en) * 2022-07-29 2026-01-15 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
AU2023377064A1 (en) * 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
DE10360745A1 (de) 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4845873B2 (ja) 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
EP2298770A1 (en) 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
WO2009058728A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Thiazole derivatives as protein kinase inhibitors
PE20091017A1 (es) 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
MX2011012993A (es) 2009-06-08 2011-12-16 Gruenenthal Gmbh Bencimidazoles, benzotiazoles y benzoxazoles, sustituidos.
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
WO2012071684A1 (en) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
CN102952118B (zh) 2011-08-17 2016-03-23 上海迪诺医药科技有限公司 聚（adp-核糖）聚合酶抑制剂、制备方法及其用途
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
HRP20161774T1 (hr) 2012-06-13 2017-02-24 F. Hoffmann - La Roche Ag Novi diazaspirocikloalkan i azaspirocikloalkan
WO2015048567A1 (en) 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Spirocyclic ebi2 modulators
WO2015051230A1 (en) 2013-10-04 2015-04-09 Drexel University Novel compositions useful for inhibiting hiv-1 infection and methods using same
LT3126352T (lt) 2014-04-04 2019-01-10 Syros Pharmaceuticals, Inc. Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai
ES2774923T3 (es) 2014-04-28 2020-07-23 China Resources Pharmaceutical Holdings Company Ltd Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
US10045979B2 (en) 2014-05-19 2018-08-14 Merial Inc. Anthelmintic compounds
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN105461693B (zh) 2014-09-26 2019-10-25 广东东阳光药业有限公司 Crth2拮抗剂化合物及其用途
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
ES2966316T3 (es) 2016-09-14 2024-04-19 Janssen Pharmaceutica Nv Inhibidores bicíclicos fusionados de interacción de MENIN-MLL
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US10266497B2 (en) 2017-05-23 2019-04-23 Abide Therapeutics, Inc. Pyrazole MAGL inhibitors
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US11014964B2 (en) 2017-07-21 2021-05-25 Sichuan Haisco Pharmaceutical Co., Ltd. Peptide amide compound and preparation method and medical use thereof
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
WO2019129121A1 (en) 2017-12-28 2019-07-04 Rpxds Co., Ltd Derivatives of phenylmethanone as fto inhibitors
CN110156674A (zh) 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
WO2019169156A1 (en) 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
CN113164443A (zh) 2018-09-26 2021-07-23 库拉肿瘤学公司 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤
KR20210083286A (ko) 2018-10-24 2021-07-06 아락세스 파마 엘엘씨 종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물
EP3883936B1 (en) 2018-11-22 2023-07-12 F. Hoffmann-La Roche AG New heterocyclic compounds
WO2020112905A1 (en) 2018-11-28 2020-06-04 Lundbeck La Jolla Research Center, Inc. Methods of treating disease with magl inhibitors
MX2021005924A (es) 2018-11-29 2021-06-30 Araxes Pharma Llc Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
CN111138358B (zh) 2019-12-17 2023-04-18 中国药科大学 Usp8抑制剂及其制备方法与应用
GEAP202316332A (en) 2021-01-29 2023-12-11 Cedilla Therapeutics Inc Cdk2 inhibitors and methods of using the same
EP4358954A4 (en) 2021-06-26 2025-09-03 Cedilla Therapeutics Inc CDK2 INHIBITORS AND METHODS OF USE THEREOF
CA3262943A1 (en) 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
WO2024026486A2 (en) 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
EP4561552A2 (en) 2022-07-29 2025-06-04 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
US20260014146A1 (en) 2022-07-29 2026-01-15 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3263133A1 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
EP4284365A1 (en) 2023-12-06
PE20240050A1 (es) 2024-01-09
MX2023008968A (es) 2023-09-22
US20230109076A1 (en) 2023-04-06
CR20230362A (es) 2023-11-23
CO2023010023A2 (es) 2023-09-08
EP4284365A4 (en) 2024-12-18
JOP20230170A1 (ar) 2023-07-27
CA3208618A1 (en) 2022-08-04
IL304728A (en) 2023-09-01
DOP2023000145A (es) 2023-10-31
KR20230142745A (ko) 2023-10-11
US12065445B2 (en) 2024-08-20
WO2022165513A1 (en) 2022-08-04
US20240174680A1 (en) 2024-05-30
JP2024505261A (ja) 2024-02-05
CN117177744A (zh) 2023-12-05
TW202239402A (zh) 2022-10-16
GEAP202316332A (en) 2023-12-11
AU2022214618A1 (en) 2023-08-17
CL2023002223A1 (es) 2023-12-29
BR112023015210A2 (pt) 2023-11-07
PH12023552079A1 (en) 2024-01-22

Similar Documents

Publication Publication Date Title
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2021002804A (es) Terapias de combinacion.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2024008551A (es) Terapias de combinacion.
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
BR112022003768A2 (pt) Compostos inibidores de perk
CO2022000266A2 (es) Inhibidores de enzimas
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CO2024009144A2 (es) Inhibidores de cinasa met
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same